Title: Meiotic susceptibility for induction of sperm with chromosomal aberrations in patients receiving combination chemotherapy for Hodgkin lymphoma.

Authors: Frias, Sara; Van Hummelen, Paul; Meistrich, Marvin L; Wyrobek, Andrew J

Published In PLoS One, (2020)

Abstract: Improvements in survival rates with gonad-sparing protocols for childhood and adolescence cancer have increased the optimism of survivors to become parents after treatment. Findings in rodents indicate that chromosomal aberrations can be induced in male germ cells by genotoxic exposures and transmitted to offspring and future generations with effects on development, fertility and health. Thus, there is a need for effective technologies to identify human sperm carrying chromosomal aberrations to assess the germ-line risks, especially for cancer survivors who have received genotoxic therapies. The time-dependent changes in the burden of sperm carrying structural chromosomal aberrations were assessed for the first time in a cancer setting, using the AM8 sperm FISH protocol which simultaneously detects abnormalities in chromosomal structure and number in sperm. Nine Hodgkin lymphoma (HL) patients provided 20 semen samples before, during, and after NOVP therapy (Novantrone, Oncovin, Velban and Prednisone) and radiation therapy that produced scattered gonadal doses from <0.05 to 0.6 Gy. Late meiosis was found to be the most sensitive to NOVP treatment for the production of sperm with chromosomal abnormalities, both in structure and number. Earlier stages of spermatogenesis were less sensitive and there was no evidence that therapy-exposed stem cells resulted in increased frequencies of sperm with abnormalities in chromosomal structure or number. This indicates that NOVP therapy may increase the risks for paternal transmission of chromosomal structural aberrations for sperm produced 32 to 45 days after a treatment with these drugs and implies that there are no excess risks for pregnancies conceived more than 6 months after this therapy. This clinical evaluation of the AM8 sperm FISH protocol indicates that it is a promising tool for assessing an individual's burden of sperm carrying chromosomal structural aberrations as well as aneuploidies after cancer therapy, with broad applications in other clinical and environmental situations that may pose aneugenic or clastogenic risks to human spermatogenesis.

PubMed ID: 33370316

MeSH Terms: Adult; Adult Germline Stem Cells/drug effects; Adult Germline Stem Cells/radiation effects; Antineoplastic Combined Chemotherapy Protocols/adverse effects*; Cancer Survivors; Chemoradiotherapy/adverse effects; Chemoradiotherapy/methods; Chromosome Aberrations/drug effects*; Chromosome Aberrations/radiation effects; Cohort Studies; Fertility Preservation; Hodgkin Disease/therapy*; Humans; In Situ Hybridization, Fluorescence/methods; Male; Meiosis/drug effects*; Meiosis/radiation effects; Mitoxantrone/adverse effects; Mutagenesis/drug effects; Mutagenesis/radiation effects; Organ Sparing Treatments/adverse effects; Organ Sparing Treatments/methods; Organs at Risk/radiation effects; Prednisone/adverse effects; Radiotherapy Dosage; Semen Analysis/methods*; Spermatogenesis/drug effects; Spermatogenesis/radiation effects; Spermatozoa/drug effects*; Spermatozoa/physiology; Spermatozoa/radiation effects; Testis/drug effects; Testis/radiation effects; Time Factors; Vinblastine/adverse effects; Vincristine/adverse effects